Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (191-200 of 294) with videos related to

Pageof 30
Sort By:
European Urology|May 17, 2019
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal TumorsYair Lotan, Stephen A Boorjian, Jingbin Zhang, et al.
JCO Precision Oncology|November 5, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 TrialGopa Iyer, Catherine M Tangen, Michal Sarfaty, et al.
BJU International|September 14, 2007
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survivalPatrick J Bastian, Georg C Hutterer, Shahrokh F Shariat, et al.
Urology|July 29, 2014
Reply by the authorsJonathan Jarow, Paul G Kluetz, Seth P Lerner, et al.
European Urology|November 23, 2006
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomyMatthew E Nielsen, Shahrokh F Shariat, Pierre I Karakiewicz, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
BJU International|December 17, 2013
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomesRichard K Lee, Hassan Abol-Enein, Walter Artibani, et al.
Urology|December 17, 2013
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshopJonathan P Jarow, Seth P Lerner, Paul G Kluetz, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
Pageof 30

Showing results (191-200 of 294) with videos related to

Sort By:
Pageof 30
European Urology|May 17, 2019
Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal TumorsYair Lotan, Stephen A Boorjian, Jingbin Zhang, et al.
JCO Precision Oncology|November 5, 2024
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 TrialGopa Iyer, Catherine M Tangen, Michal Sarfaty, et al.
BJU International|September 14, 2007
Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survivalPatrick J Bastian, Georg C Hutterer, Shahrokh F Shariat, et al.
Urology|July 29, 2014
Reply by the authorsJonathan Jarow, Paul G Kluetz, Seth P Lerner, et al.
European Urology|November 23, 2006
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomyMatthew E Nielsen, Shahrokh F Shariat, Pierre I Karakiewicz, et al.
JAMA Network Open|August 6, 2024
Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma: A Secondary Analysis of a Randomized Clinical TrialShuchi Gulati, Catherine Tangen, Christopher W Ryan, et al.
JAMA Network Open|July 9, 2024
Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 TrialGeorges Gebrael, Yeonjung Jo, Umang Swami, et al.
BJU International|December 17, 2013
Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomesRichard K Lee, Hassan Abol-Enein, Walter Artibani, et al.
Urology|December 17, 2013
Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshopJonathan P Jarow, Seth P Lerner, Paul G Kluetz, et al.
European Urology Oncology|November 9, 2024
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216Umang Swami, Yeonjung Jo, Arshit Narang, et al.
Pageof 30